Cargando…

Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis

Background: Chronic drug-induced liver injury (DILI) occurs in up to 20% of all DILI patients. It presents a chronic pattern with persistent or relapsed episodes and may even progress to cirrhosis. However, its underlying development mechanism is poorly understood. Aims: To find serum metabolite sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuai-shuai, Huang, Ying, Guo, Yu-ming, Li, Shan-shan, Shi, Zhuo, Niu, Ming, Zou, Zheng-sheng, Xiao, Xiao-he, Wang, Jia-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039323/
https://www.ncbi.nlm.nih.gov/pubmed/33855035
http://dx.doi.org/10.3389/fmed.2021.640799
_version_ 1783677564586295296
author Chen, Shuai-shuai
Huang, Ying
Guo, Yu-ming
Li, Shan-shan
Shi, Zhuo
Niu, Ming
Zou, Zheng-sheng
Xiao, Xiao-he
Wang, Jia-bo
author_facet Chen, Shuai-shuai
Huang, Ying
Guo, Yu-ming
Li, Shan-shan
Shi, Zhuo
Niu, Ming
Zou, Zheng-sheng
Xiao, Xiao-he
Wang, Jia-bo
author_sort Chen, Shuai-shuai
collection PubMed
description Background: Chronic drug-induced liver injury (DILI) occurs in up to 20% of all DILI patients. It presents a chronic pattern with persistent or relapsed episodes and may even progress to cirrhosis. However, its underlying development mechanism is poorly understood. Aims: To find serum metabolite signatures of chronic DILI with or without cirrhosis, and to elucidate the underlying mechanism. Methods: Untargeted metabolomics coupled with pattern recognition approaches were used to profile and extract metabolite signatures from 83 chronic DILI patients, including 58 non-cirrhosis (NC) cases, 14 compensated cirrhosis (CC) cases, and 11 decompensated cirrhosis (DC) cases. Results: Of the 269 annotated metabolites associated with chronic DILI, metabolic fingerprints associated with cirrhosis (including 30 metabolites) and decompensation (including 25 metabolites), were identified. There was a significantly positive correlation between cirrhosis-associated fingerprint (eigenmetabolite) and the aspartate aminotransferase-to-platelet ratio index (APRI) (r = 0.315, P = 0.003). The efficacy of cirrhosis-associated eigenmetabolite coupled with APRI to identify cirrhosis from non-cirrhosis patients was significantly better than APRI alone [area under the curve (AUC) value 0.914 vs. 0.573]. The decompensation-associated fingerprint (eigenmetabolite) can effectively identify the compensation and decompensation periods (AUC value 0.954). The results of the metabolic fingerprint pathway analysis suggest that the blocked tricarboxylic acid cycle (TCA cycle) and intermediary metabolism, excessive accumulation of bile acids, and perturbed amino acid metabolism are potential mechanisms in the occurrence and development of chronic DILI-associated cirrhosis. Conclusions: The metabolomic fingerprints characterize different stages of chronic DILI progression and deepen the understanding of the metabolic reprogramming mechanism of chronic DILI progression to cirrhosis.
format Online
Article
Text
id pubmed-8039323
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80393232021-04-13 Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis Chen, Shuai-shuai Huang, Ying Guo, Yu-ming Li, Shan-shan Shi, Zhuo Niu, Ming Zou, Zheng-sheng Xiao, Xiao-he Wang, Jia-bo Front Med (Lausanne) Medicine Background: Chronic drug-induced liver injury (DILI) occurs in up to 20% of all DILI patients. It presents a chronic pattern with persistent or relapsed episodes and may even progress to cirrhosis. However, its underlying development mechanism is poorly understood. Aims: To find serum metabolite signatures of chronic DILI with or without cirrhosis, and to elucidate the underlying mechanism. Methods: Untargeted metabolomics coupled with pattern recognition approaches were used to profile and extract metabolite signatures from 83 chronic DILI patients, including 58 non-cirrhosis (NC) cases, 14 compensated cirrhosis (CC) cases, and 11 decompensated cirrhosis (DC) cases. Results: Of the 269 annotated metabolites associated with chronic DILI, metabolic fingerprints associated with cirrhosis (including 30 metabolites) and decompensation (including 25 metabolites), were identified. There was a significantly positive correlation between cirrhosis-associated fingerprint (eigenmetabolite) and the aspartate aminotransferase-to-platelet ratio index (APRI) (r = 0.315, P = 0.003). The efficacy of cirrhosis-associated eigenmetabolite coupled with APRI to identify cirrhosis from non-cirrhosis patients was significantly better than APRI alone [area under the curve (AUC) value 0.914 vs. 0.573]. The decompensation-associated fingerprint (eigenmetabolite) can effectively identify the compensation and decompensation periods (AUC value 0.954). The results of the metabolic fingerprint pathway analysis suggest that the blocked tricarboxylic acid cycle (TCA cycle) and intermediary metabolism, excessive accumulation of bile acids, and perturbed amino acid metabolism are potential mechanisms in the occurrence and development of chronic DILI-associated cirrhosis. Conclusions: The metabolomic fingerprints characterize different stages of chronic DILI progression and deepen the understanding of the metabolic reprogramming mechanism of chronic DILI progression to cirrhosis. Frontiers Media S.A. 2021-03-29 /pmc/articles/PMC8039323/ /pubmed/33855035 http://dx.doi.org/10.3389/fmed.2021.640799 Text en Copyright © 2021 Chen, Huang, Guo, Li, Shi, Niu, Zou, Xiao and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Chen, Shuai-shuai
Huang, Ying
Guo, Yu-ming
Li, Shan-shan
Shi, Zhuo
Niu, Ming
Zou, Zheng-sheng
Xiao, Xiao-he
Wang, Jia-bo
Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title_full Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title_fullStr Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title_full_unstemmed Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title_short Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis
title_sort serum metabolomic analysis of chronic drug-induced liver injury with or without cirrhosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039323/
https://www.ncbi.nlm.nih.gov/pubmed/33855035
http://dx.doi.org/10.3389/fmed.2021.640799
work_keys_str_mv AT chenshuaishuai serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT huangying serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT guoyuming serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT lishanshan serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT shizhuo serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT niuming serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT zouzhengsheng serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT xiaoxiaohe serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis
AT wangjiabo serummetabolomicanalysisofchronicdruginducedliverinjurywithorwithoutcirrhosis